0.5149
3.21%
-0.0171
After Hours:
.515
0.000100
+0.02%
Opgen Inc stock is currently priced at $0.5149, with a 24-hour trading volume of 436.56K.
It has seen a -3.21% decreased in the last 24 hours and a -31.35% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.5453 pivot point. If it approaches the $0.5105 support level, significant changes may occur.
Previous Close:
$0.532
Open:
$0.54
24h Volume:
436.56K
Market Cap:
$6.16M
Revenue:
$3.07M
Net Income/Loss:
$-26.16M
P/E Ratio:
-0.0427
EPS:
-12.05
Net Cash Flow:
$-17.84M
1W Performance:
-18.27%
1M Performance:
-31.35%
6M Performance:
-22.22%
1Y Performance:
-37.96%
Opgen Inc Stock (OPGN) Company Profile
Name
Opgen Inc
Sector
Industry
Phone
240 813 1260
Address
9717 Key West Avenue, Suite 100, Rockville, MD
Opgen Inc Stock (OPGN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-01-19 | Initiated | Alliance Global Partners | Buy |
Feb-07-18 | Reiterated | H.C. Wainwright | Buy |
Jun-29-16 | Initiated | Rodman & Renshaw | Buy |
Opgen Inc Stock (OPGN) Latest News
OpGen Receives Nasdaq Notice Regarding Delayed Form 10-K
GlobeNewswire Inc.
Crude Oil Moves Lower; TD SYNNEX Earnings Top Estimates
Benzinga
Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga
Dow Gains 100 Points; McCormick Posts Upbeat Results
Benzinga
Nasdaq Gains Over 50 Points; US Durable Goods Orders Rise In February
Benzinga
Why Stoke Therapeutics Shares Are Trading Higher By Around 70%; Here Are 20 Stocks Moving Premarket
Benzinga
Opgen Inc Stock (OPGN) Financials Data
Opgen Inc (OPGN) Revenue 2024
OPGN reported a revenue (TTM) of $3.07 million for the quarter ending September 30, 2023, a -7.28% decline year-over-year.
Opgen Inc (OPGN) Net Income 2024
OPGN net income (TTM) was -$26.16 million for the quarter ending September 30, 2023, a +22.04% increase year-over-year.
Opgen Inc (OPGN) Cash Flow 2024
OPGN recorded a free cash flow (TTM) of -$17.84 million for the quarter ending September 30, 2023, a +13.34% increase year-over-year.
Opgen Inc (OPGN) Earnings per Share 2024
OPGN earnings per share (TTM) was -$6.51 for the quarter ending September 30, 2023, a +64.54% growth year-over-year.
About Opgen Inc
OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.
Cap:
|
Volume (24h):